Relapsed/refractory adult acute myeloid leukemia (AML)
Showing 1 - 25 of >10,000
Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse Trial in Miami (Bomedemstat,
Recruiting
- Acute Myeloid Leukemia
- +2 more
-
Miami, FloridaUniversity of Miami
Dec 22, 2022
Relapsed Adult AML, Refractory AML Trial in Milwaukee (Navitoclax Dose Level -1, Navitoclax Dose Level 0, Navitoclax Dose Level
Not yet recruiting
- Relapsed Adult AML
- Refractory AML
- Navitoclax Dose Level -1
- +10 more
-
Milwaukee, WisconsinFroedtert Hospital & the Medical College of Wisconsin
Aug 17, 2023
AML, Adult Trial (Pharmacoscopy, Clinical standard-of-care (physician's choice))
Not yet recruiting
- AML, Adult
- Pharmacoscopy
- Clinical standard-of-care (physician's choice)
- (no location specified)
Nov 20, 2023
AML, Adult Trial in Tianjin (QN-023a, Cyclophosphamid, Fludarabine)
Recruiting
- AML, Adult
- QN-023a
- +3 more
-
Tianjin, Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Nov 3, 2022
Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Seattle (SC-DARIC33)
Recruiting
- Acute Myeloid Leukemia
- +2 more
- SC-DARIC33
-
Seattle, WashingtonSeattle Children's Hospital
Sep 6, 2022
AML, Adult, Refractory AML, Relapsed Adult AML Trial in France (AzaCITIDine Oral Tablet, Xospata)
Not yet recruiting
- AML, Adult
- +4 more
- AzaCITIDine Oral Tablet
- Xospata
-
Amiens, France
- +19 more
Sep 1, 2023
AML, Adult Trial in Hangzhou (CLL1 CAR-NK cell injection)
Recruiting
- AML, Adult
- CLL1 CAR-NK cell injection
-
Hangzhou, Zhejiang, ChinaClinical research ethics committee of the first affiliated hospi
Aug 30, 2023
Leukemia, Myeloid, Acute, Relapsed Adult AML, Refractory Leukemia Trial in Xiamen (venetoclax combining chidamide and
Recruiting
- Leukemia, Myeloid, Acute
- +2 more
- venetoclax combining chidamide and azacitidine (VCA)
-
Xiamen, Fujian, ChinaBing Xu
Aug 1, 2022
Acute Myeloid Leukemia, Adult, MDS Trial in Marseille, Paris, Pierre-BĂ©nite (ABD-3001)
Active, not recruiting
- Acute Myeloid Leukemia, Adult
- Myelodysplastic Syndromes
-
Marseille, France
- +2 more
Jan 19, 2023
Relapsed Adult AML, Primary Refractory Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia Trial in United States
Recruiting
- Relapsed Adult AML
- +2 more
- Specialty Palliative Care
- Primary Palliative Care
-
Boston, Massachusetts
- +3 more
Aug 12, 2022
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute Trial in United States (CYNK-001)
Recruiting
- Leukemia
- +19 more
- CYNK-001
-
Denver, Colorado
- +9 more
Sep 9, 2022
Immunotherapy, Refractory Leukemia, Relapsed Adult AML Trial in Suzhou (Visilizumab)
Recruiting
- Immunotherapy
- +3 more
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Dec 2, 2021
Leukemia, Acute Myeloid Leukemia, Relapsed/Refractory Acute Myeloid Leukemia Trial in Tianjin (MAX-40279-01)
Recruiting
- Leukemia
- +3 more
-
Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Sep 29, 2021
Acute Myelogenous Leukemia in Relapse, Acute Myelogenous Leukemia, Relapsed, Adult, Acute Myelogenous Leukemia, Adult Trial in
Terminated
- Acute Myelogenous Leukemia in Relapse
- +4 more
-
Tucson, Arizona
- +12 more
Aug 18, 2022
Acute Myeloid Leukemia, Relapsed Adult AML Trial (Lintuzumab-Ac225, Venetoclax, Azacitidine)
Not yet recruiting
- Acute Myeloid Leukemia
- Relapsed Adult AML
- Lintuzumab-Ac225
- +2 more
- (no location specified)
Feb 22, 2022
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute Trial in Japan, United States (DSP-5336)
Recruiting
- Leukemia, Myeloid, Acute
- Leukemia, Lymphocytic, Acute
-
Houston, Texas
- +5 more
May 31, 2022
Myelogenous Leukemia, Acute Trial in Ramat Gan (Bisantrene, Fludarabine, Clofarabine)
Recruiting
- Myelogenous Leukemia, Acute
- Bisantrene
- +2 more
-
Ramat Gan, IsraelChaim Sheba Medical Center
Sep 21, 2021
Acute Myeloid Leukemia, Refractory Acute Leukemia, Relapsed Adult AML Trial in Suzhou (CAHAG regimen, Placebo regimen)
Recruiting
- Acute Myeloid Leukemia
- +2 more
- CAHAG regimen
- Placebo regimen
-
Suzhou, Jiangsu, ChinaThe First Affliated Hospital of Soochow University
Oct 10, 2021
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Neuroblastoma Trial in Worldwide (Idasanutlin, Venetoclax,
Recruiting
- Acute Myeloid Leukemia (AML)
- +3 more
- Idasanutlin
- +6 more
-
Phoenix, Arizona
- +19 more
Jan 18, 2023